- Home
- MXCT
MXCT
MaxCyte Inc.
as 12-20-2024 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 375.0M | IPO Year: | 2021 |
| Target Price: | $9.50 | AVG Volume (30 days): | 704.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.17 - $5.55 | Next Earning Date: | 11-06-2024 |
| Revenue: | $45,599,000 | Revenue Growth: | 19.85% |
| Revenue Growth (this year): | -7.2% | Revenue Growth (next year): | 21.27% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Johnston John Joseph | MXCT | Director | Dec 6 '24 | Sell | $3.75 | 3,000 | $11,327.55 | 141,950 | |
| Erck Stanley C | MXCT | Director | Nov 1 '24 | Sell | $3.72 | 47,689 | $177,403.08 | 269,118 | |
| Johnston John Joseph | MXCT | Director | Oct 28 '24 | Sell | $3.72 | 3,000 | $11,166.00 | 141,950 | |
| Erck Stanley C | MXCT | Director | Oct 1 '24 | Sell | $3.75 | 47,689 | $178,751.93 | 269,118 | |
| Johnston John Joseph | MXCT | Director | Sep 26 '24 | Sell | $3.82 | 3,000 | $11,460.00 | 141,950 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
MT Newswires
13 days ago
MaxCyte Reduces 15% of Workforce, Raises 2024 Revenue Guidance
GlobeNewswire
13 days ago
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
Simply Wall St.
a month ago
This MaxCyte Insider Increased Their Holding In The Last Year
GlobeNewswire
a month ago
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
GuruFocus.com
a month ago
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...
Zacks
a month ago
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
GlobeNewswire
2 months ago
MaxCyte to Participate in Two Upcoming Investor Conferences
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.